FCGR3A and cancer: Therefore, F9H4 inhibits CD16a/b shedding in a highly specific manner and is a new opportunity to enhance the efficacy of tumor cell-opsonizing antibodies for cancer immunotherapy by promoting Fc receptor engagement.